B-OM is going to be a blockbuster:
Compounds For Use In Treatment Of Mucositis
United States: issued 08/12/14, 10/13/15, and 10/4/16; allowed 06/14/17;
Japan: issued 11/06/15;
Taiwan: issued 2/11/16;
China: issued 04/20/16;
South Africa: issued 04/29/15
Australia: issued 10/6/16
Pending: Europe, Australia, Brazil, Canada, Israel, Russia, and South Korea
Patents Expire: 2032
Category 1
Methods of treating mucositis with Brilacidin and related compounds, and compositions of Brilacidin and palifermin
"Head and Neck Cancer (HNC) patients—comprising an estimated 65,000 newly diagnosed cases in the U.S. alone in 2017, and an estimated 700,000 worldwide (source: GLOBOCAN)—are at the greatest risk of developing OM (a 90 to 100 percent rate of occurrence). By 2030, the global incidence of HNC cases is expected to exceed 1 million per year. Moreover, between 25 and 60 percent of cancer patients, regardless of cancer type, also will experience OM."
Compounds For Use In Treatment Of Mucositis
United States: issued 08/12/14, 10/13/15, and 10/4/16; allowed 06/14/17;
Japan: issued 11/06/15;
Taiwan: issued 2/11/16;
China: issued 04/20/16;
South Africa: issued 04/29/15
Australia: issued 10/6/16
Pending: Europe, Australia, Brazil, Canada, Israel, Russia, and South Korea
Patents Expire: 2032
Category 1
Methods of treating mucositis with Brilacidin and related compounds, and compositions of Brilacidin and palifermin
"Head and Neck Cancer (HNC) patients—comprising an estimated 65,000 newly diagnosed cases in the U.S. alone in 2017, and an estimated 700,000 worldwide (source: GLOBOCAN)—are at the greatest risk of developing OM (a 90 to 100 percent rate of occurrence). By 2030, the global incidence of HNC cases is expected to exceed 1 million per year. Moreover, between 25 and 60 percent of cancer patients, regardless of cancer type, also will experience OM."
6